Browse medicines, page 18 of 37

Use listed on the medicine record

Reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration

Use listed on the medicine record

SUBLIME D-LIFT DMAE Lift Serum ind

Use listed on the medicine record

The topical treatment of acute pain due to minor strains, sprains, and contusions

Use listed on the medicine record

Use as monotherapy only

Use listed on the medicine record

The topical treatment of adults and pediatric patients 2 years of age and older with mild to moderate atopic dermatitis

Use listed on the medicine record

Moderate-to-severe pruritus associated with chronic kidney disease

Use listed on the medicine record

MOTOFEN ® is indicated as adjunctive therapy in the management of acute nonspecific diarrhea and acute exacerbations of chronic functional diarrhea.

Use listed on the medicine record

Acute or long-term use for symptomatic treatment of the following

Use listed on the medicine record

Inflammation and pain associated with ocular surgery

Use listed on the medicine record

Moderate to moderately severe pain

Use listed on the medicine record

The prevention and treatment of nausea, vomiting, or vertigo of motion sickness

Use listed on the medicine record

OTC Purpose Section

Use listed on the medicine record

The symptomatic relief of patients with interstitial cystitis

Use listed on the medicine record

Diphenoxylate Hydrochloride and Atropine Sulfate Tablets USP are indicated as adjunctive therapy in the management of diarrhea in patients 13 years of age and older.

Use listed on the medicine record

Directions: Wash hands before and after applying, adults and children12 years of age and older: Apply to affected area not more than 3 to 4 times daily. Children under 12 years of age: Consult a doctor.

Use listed on the medicine record

MODEYSO is indicated for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Use listed on the medicine record

The signs and symptoms of BPH

Use listed on the medicine record

Thymidine kinase 2 deficiency

Use listed on the medicine record

Secondary hyperparathyroidism

Use listed on the medicine record

Use by females of reproductive potential to prevent pregnancy

Use listed on the medicine record

Anesthetizing accessible mucous membranes (e

Use listed on the medicine record

Amyotrophic lateral sclerosis

Use listed on the medicine record

The topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes

Use listed on the medicine record

CERDELGA is indicated for the long-term treatment of adult patients with Gaucher disease type 1 (GD1) who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test [see Dosage and Administration (2.1) ] . CERDELGA is a glucosylceramide synthase inhibitor indicated for the long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test.

Use listed on the medicine record

HIV-1 infection

Use listed on the medicine record

Unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-authorized test

Use listed on the medicine record

Low-density lipoprotein cholesterol

Use listed on the medicine record

ENSACOVE is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)as detected by an FDA-approved test [see Dosage and Administration ( 2.1 )] who have not previously received an ALK-inhibitor. ENSACOVE is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test who have not previously received an ALK-inhibitor. ( 1 , 2.1 )

Use listed on the medicine record

Erlotinib tablets are a kinase inhibitor indicated for: • The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. ( 1.1 ) • First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.

Use listed on the medicine record

Erythromycin lactobionate for injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. Intravenous therapy should be replaced by oral administration at the appropriate time.

Use listed on the medicine record

Discomfort and aches associated with PMS*

Use listed on the medicine record

Lipiodol is an oil-based radio-opaque contrast agent indicated for: hysterosalpingography in adults lymphography in adult and pediatric patients selective hepatic intra-arterial use for imaging tumors in adults with known hepatocellular carcinoma (HCC) Lipiodol is an oil-based radiopaque contrast agent indicated for: hysterosalpingography in adults lymphography in adult and pediatric patients selective hepatic intra-arterial use for imaging tumors in adults with known hepatocellular carcinoma (HCC)

Use listed on the medicine record

Moderately to severely active ulcerative colitis

Use listed on the medicine record

Fenoprofen calcium is indicated for: • Relief of mild to moderate pain in adults • Relief of the signs and symptoms of rheumatoid arthritis • Relief of the signs and symptoms of osteoarthritis Fenoprofen calcium is a nonsteroidal anti-inflammatory drug indicated for: • Relief of mild to moderate pain in adults. ( 1 ) • Relief of the signs and symptoms of rheumatoid arthritis. ( 1 ) • Relief of the signs and symptoms of osteoarthritis. ( 1 )

Use listed on the medicine record

Iron deficiency anemia

Use listed on the medicine record

Serum phosphorus levels

Use listed on the medicine record

SUGGESTED USE Adults: One (1) tablet daily, preferably after meals or as directed by the doctor. Children: As directed by the doctor.

Use listed on the medicine record

Fexinidazole Tablets are indicated for the treatment of both the first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in patients 6 years of age and older and weighing at least 20 kg. Fexinidazole Tablets is a nitroimidazole antimicrobial, indicated for the treatment of both first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in patients 6 years of age and older and weighing at least 20 kg.

Use listed on the medicine record

Acute otitis externa (AOE) with or without an otowick, caused by susceptible strains of Pseudomonas aeruginosa and Staphylococcus aureus

Use listed on the medicine record

TASCENSO ODT is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. TASCENSO ODT is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. ( 1 )